Although deletion of HIF1α in cDCs results in increased obesity-tissue inflammation, therapeutic treatment with the selective HIF1α inhibitor PX-478 slows down the progression of obesity-induced adipose tissue inflammation55. Here, HIF1A is linked to obesity due to melanocortin 4 receptor deficiency.